Literature DB >> 26818632

Problems in the Descriptions of the Psychiatric Inclusion and Exclusion Criteria in Publications of Antidepressant Efficacy Trials: A Qualitative Review and Recommendations for Improved Clarity.

Mark Zimmerman1, Matthew Multach2, Emily Walsh2, Lia K Rosenstein2, Douglas Gazarian2, Heather L Clark2.   

Abstract

We recently conducted a comprehensive review of the psychiatric inclusion and exclusion criteria used in 170 placebo-controlled antidepressant efficacy trials (AETs) that were published between 1995 and 2014. In conducting this literature review, we identified a number of instances in which the descriptions of the inclusion/exclusion criteria were vague, redundant, or difficult to interpret. In the present article, we describe nine problems we encountered in our literature review. We recommend that future publications follow the examples found in a few studies in which the inclusion/exclusion criteria are clearly defined and listed in a table.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26818632     DOI： 10.1007/s40263-016-0314-y

Source DB:  PubMed          Journal:  CNS Drugs        ISSN： 1172-7047            Impact factor:   5.749


  78 in total

1.  Patients excluded from an antidepressant efficacy trial.

Authors:  T Partonen; S Sihvo; J K Lönnqvist
Journal:  J Clin Psychiatry       Date:  1996-12       Impact factor: 4.384

2.  Symptomatic volunteers: another patient dimension for clinical trials.

Authors:  B Brauzer; B J Goldstein
Journal:  J Clin Pharmacol New Drugs       Date:  1973 Feb-Mar

3.  Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression.

Authors:  J P Feighner; K Overø
Journal:  J Clin Psychiatry       Date:  1999-12       Impact factor: 4.384

4.  Efficacy and tolerability of Hypericum extract STW 3-VI in patients with moderate depression: a double-blind, randomized, placebo-controlled clinical trial.

Authors:  Ralf Uebelhack; Joerg Gruenwald; Hans-Joachim Graubaum; Regina Busch
Journal:  Adv Ther       Date:  2004 Jul-Aug       Impact factor: 3.845

5.  A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression.

Authors:  Sanjay Dubé; Mary Anne Dellva; Marcia Jones; William Kielbasa; Robert Padich; Amitabh Saha; Prasad Rao
Journal:  J Psychiatr Res       Date:  2009-11-11       Impact factor: 4.791

6.  Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial.

Authors:  Patrice Boyer; Stuart Montgomery; Ulla Lepola; Jean-Michel Germain; Claudine Brisard; Rita Ganguly; Sudharshan K Padmanabhan; Karen A Tourian
Journal:  Int Clin Psychopharmacol       Date:  2008-09       Impact factor: 1.659

7.  The emerging epidemiology of hypomania and bipolar II disorder.

Authors:  J Angst
Journal:  J Affect Disord       Date:  1998-09       Impact factor: 4.839

8.  Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study.

Authors:  Robert J Bielski; Lynn Cunningham; Joseph P Horrigan; Peter D Londborg; Ward T Smith; Kenneth Weiss
Journal:  J Clin Psychiatry       Date:  2008-04       Impact factor: 4.384

9.  A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.

Authors:  Jay D Amsterdam
Journal:  J Clin Psychiatry       Date:  2003-02       Impact factor: 4.384

10.  Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder.

Authors:  Jean-Philippe Boulenger; Henrik Loft; Christina Kurre Olsen
Journal:  Int Clin Psychopharmacol       Date:  2014-05       Impact factor: 1.659
View more
  3 in total

1.  Isobolographic analysis of the antidepressant interaction in two-drug combinations of citalopram, bupropion, and scopolamine in mice.

Authors:  Mohammad-Hossein Mohammadi-Mahdiabadi-Hasani; Mohaddeseh Ebrahimi-Ghiri; Fatemeh Khakpai; Mohammad-Reza Zarrindast
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-04-19       Impact factor: 3.000

2.  Mouse strain differences in SSRI sensitivity correlate with serotonin transporter binding and function.

Authors:  Zeng-Liang Jin; Xiao-Fei Chen; Yu-Hua Ran; Xiao-Rong Li; Jie Xiong; Yuan-Yuan Zheng; Na-Na Gao; Yun-Feng Li
Journal:  Sci Rep       Date:  2017-08-17       Impact factor: 4.379

3.  The Generalizability of Randomized Controlled Trials of Self-Guided Internet-Based Cognitive Behavioral Therapy for Depressive Symptoms: Systematic Review and Meta-Regression Analysis.

Authors:  Lorenzo Lorenzo-Luaces; Emily Johns; John R Keefe
Journal:  J Med Internet Res       Date:  2018-11-09       Impact factor: 5.428
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.